http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Furukawa Yuki (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Marumo Yoshiaki,Yoshida Takashi,Furukawa Yuki,Ina Kenji,Kamiya Ayumi,Kataoka Takae,Kayukawa Satoshi 대한백신학회 2023 Clinical and Experimental Vaccine Research Vol.12 No.4
Purpose: Patients with hematological malignancies are at an increased risk of severe infection with coronavirus disease 2019 (COVID-19). However, developing an adequate immune response after vaccination is difficult, especially in patients with lymphoid neoplasms. Since the long-term effects of the BNT162b2 vaccine are unclear, the humoral immune response 5 months after the two vaccinations in patients with hematological disorders was analyzed. Materials and Methods: Samples were collected from 96 patients vaccinated twice with BNT162b2 and treated with at least one line of an antitumor or immunosuppressive drug in our hospital from November 2021 to February 2022. Serum anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) spike (S) antibody titers were analyzed. Patients were age- and sex-matched using propensity matching and compared with a healthy control group. Patients with serum anti-SARS-CoV-2 S antibodies were defined as ‘responder’ if >50 U/mL. The patients had B-cell non-Hodgkin lymphoma (B-NHL), multiple myeloma, chronic myeloid leukemia, etc. Results: Patients had significantly low antibody levels (median, 55.3 U/mL vs. 809.8 U/mL; p<0.001) and a significantly low response rate (p<0.001). Multivariate analysis showed that patients with B-NHL, aged >72 years, were associated with a low response to vaccination. There were no significant differences between patients with chronic myeloid leukemia and healthy controls. Conclusion: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.
-
Status of a Carbon-Ion Therapy Facility and Development for Advanced Treatment
Atsushi Kitagawa,Takashi Fujita,Akifumi Fukumura,Takuji Furukawa,Taku Inaniwa,Yoshiyuki Iwata,Tatsuaki Kanai,Mitsutaka Kanazawa,Nobuyuki Kanematsu,Yuki Kase,Masataka Komori,Koji Noda,Yumiko Ohno,Shinj 한국물리학회 2008 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.53 No.6
Over 3000 cancer patients have already been treated with 140- to 400-MeV/n carbon beams produced by the heavy ion medical accelerator in Chiba (HIMAC) at the National Institute of Radiological Sciences (NIRS) since 1994. These clinical results have clearly verified the advantages of carbon ions. Based on our experience at HIMAC, a hospital-specific facility optimized for carbon-ion therapy has been designed. The prototype developments of an electron cyclotron resonance (ECR) ion source, a radio frequency quadruple (RFQ) linac, an inter digital H (IH) linac, an acceleration system of synchrotron, a beam-delivery system and other key-technology parts have been successfully finished. Thus, in co-operation with NIRS, Gunma University has been constructing a carbon-therapy facility since April, 2006. If the present clinical results are to be improved, it is necessary to create a more accurate dose distribution on tumors without an undesired dose being deposited in normal tissue. Beam-scanning methods with respiration-gated irradiation are especially important to treat a cancer tumor located in the trunk of a patient. Over 3000 cancer patients have already been treated with 140- to 400-MeV/n carbon beams produced by the heavy ion medical accelerator in Chiba (HIMAC) at the National Institute of Radiological Sciences (NIRS) since 1994. These clinical results have clearly verified the advantages of carbon ions. Based on our experience at HIMAC, a hospital-specific facility optimized for carbon-ion therapy has been designed. The prototype developments of an electron cyclotron resonance (ECR) ion source, a radio frequency quadruple (RFQ) linac, an inter digital H (IH) linac, an acceleration system of synchrotron, a beam-delivery system and other key-technology parts have been successfully finished. Thus, in co-operation with NIRS, Gunma University has been constructing a carbon-therapy facility since April, 2006. If the present clinical results are to be improved, it is necessary to create a more accurate dose distribution on tumors without an undesired dose being deposited in normal tissue. Beam-scanning methods with respiration-gated irradiation are especially important to treat a cancer tumor located in the trunk of a patient.
-
Low Dose Ultraviolet Al (340-400 nm) Phototherapy for Erythrodermic Cutaneous T-cell Lymphoma
Uede, Koji,Hiroi, Akihisa,Nakamura, Tomoyuki,Kishi, Tomoo,Yamamoto, Yuki,Furukawa, Fukumi Korean Society of Photoscience 2002 Journal of Photosciences Vol.9 No.2
Three patients suffering from widespread erythrodermic cutaneous T-cell lymphoma were treated with low-dose UVAI phototherapy with a single dose of 20 - 30J/$cm^2$, resulting in cumulative doses of 520 - 1890 J/$cm^2$. Two patients showed complete responses, while other had a partial improvement.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
